Pharmaceuticals

Rundu Pharma

Rundu Pharma FY2026 Q1 Earning Release on April 28 Pre-Market BJT

Rundu Pharma to Release FY2025 Earnings Report on April 28, Pre-Market BJT

Rundu Pharma released FY2025 9 Months Earnings on October 31 Pre-Market (BJT), actual revenue CNY 884.4 M, actual EPS CNY -0.1211

Rundu Pharma released FY2025 Q3 earnings on October 31 Pre-Market (BJT), actual revenue CNY 336.33 M, actual EPS CNY -0.0503

Rundu Pharma to Release FY2025 Q3 Earnings on October 31, Pre-Market BJT

Rundu Pharma released FY2025 Semi-Annual Earnings on August 29 After-Market (BJT), with actual revenue of CNY 548.07 M and EPS of CNY -0.11

Rundu Pharma released FY2025 Q2 earnings on August 29 After-Market (BJT), actual revenue CNY 293.36 M, actual EPS CNY -0.0807

Rundu Pharma to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

Controlling Shareholder Li Xi Plans to Reduce Holdings in Rundu Pharmaceutical

Rundu Pharmaceutical Secretary Answers Investors' Questions on Nicotine Production and Sales and Shareholder Numbers

Rundu Pharmaceutical Expected to Report Loss in First Half of 2025

Rundu Pharmaceutical Responds to Research Team Stability and Profit Decline Issues

Rundi Pharmaceutical Obtains Drug Registration Certificate for Moxifloxacin Hydrochloride Tablets

Runda Pharmaceutical Passes Brazilian ANVISA GMP Certification

Rundu Pharmaceutical Successfully Passes FDA Inspection

Rundu Pharmaceutical Responds to Investor Questions on R&D and Profitability

Rundu Co. completes Phase IIIb clinical trials for N-Desmethyldoxaphyllum hydrochloride injection

Rundu Pharmaceutical Reports Significant Increase in Nicotine Sales

Company Focuses on Health Sector, Driving Innovation and Technological Upgrades

Zhuhai Rundu Pharmaceutical Submits 3 New Trademark Applications

512290

002038

002923

516820

159849

Innovative drug concept stocks rapidly plummeted, with NEPTUNUS hitting the daily limit, RemeGen falling more than 10%, and many stocks including Cosunter, Rundu Pharma, Sunshine Guojian Pharmaceutical, SL PHARM, and HITECK dropping more than 6%

Wallstreetcn

Guotai CSI Bio-medicine ETF

SL PHARM

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

RemeGen

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

NEPTUNUS

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Sunshine Guojian Pharmaceutical

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

HITECK

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Cosunter

159892

Innovative drug concept repeatedly active, ALK straight to the daily limit, Rundu Pharma previously sealed the board, InventisBio, Junshi Biosciences, HWPC, and Biokin Pharmaceutical rose more than 6%

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

InventisBio

BIOKIN PHARMACEUTICAL

HWPC

Minsheng Royal CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

Junshi Biosciences

ChinaAMC CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

According to the Zhitong Finance APP, Rundu Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 884 million yuan, a year-on-year increase of 0.85%. The net loss attributable to shareholders of the listed company was 54.6878 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 66.1263 million yuan

Zhitong

Rundu Pharma released its performance for the first three quarters, with a net loss attributable to the parent company of 54.6878 million yuan

According to the Zhitong Finance APP, Rundu Pharma announced that the company recently received the "Approval Notice for the Market Application of Isosorbide Mononitrate" issued by the National Medical Products Administration. This product is suitable for the long-term treatment of coronary heart disease; prevention of angina pectoris; treatment of persistent angina pectoris after myocardial infarction; and in combination with digoxin and/or diuretics for the treatment of chronic congestive heart failure: treatment of pulmonary hypertension

Rundu Pharma: Application for the listing of isosorbide mononitrate chemical raw materials has been approved

Rundu Pharma announced that from May 14, 2025, to May 16, 2025, the company underwent an on-site GMP inspection of the active pharmaceutical ingredient CEP by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Recently, the company received the "Inspection Certificate" issued by EDQM, and the inspection was successfully passed

Rundu Pharma: Passed the on-site inspection by the European Medicines Agency

According to the Zhitong Finance APP, Rundu Pharma announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration, involving the drug: Valsartan and Amlodipine Tablets (I). This product is suitable for the treatment of primary hypertension. It is used for patients whose blood pressure cannot be adequately controlled with monotherapy

Rundu Pharma: Valsartan Amlodipine Tablets (I) Obtains Drug Registration Certificate

Rundu Pharma announced that its operating revenue in the first half of 2025 was CNY 548 million, a year-on-year decrease of 8.22%. The net profit attributable to shareholders of the listed company was -CNY 36.1931 million, a year-on-year decrease of 195.75%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital through reserves

Rundu Pharma: Net loss of 36.1931 million yuan in the first half of 2025

On the evening of August 25th, Rundu Pharma announced that the company recently received the "Drug Registration Certificate" for isosorbide mononitrate tablets issued by the National Medical Products Administration. This product is suitable for the long-term treatment of coronary heart disease; prevention of angina pectoris; treatment of persistent angina pectoris after myocardial infarction; and in combination with digoxin and/or diuretics for the treatment of chronic congestive heart failure

Rundu Pharma: Obtained the drug registration certificate for Isosorbide Mononitrate Tablets

According to the Zhitong Finance APP, Rundu Pharma announced that the company recently received the "Approval Notice for the Market Application of Chemical Raw Materials" issued by the National Medical Products Administration for hydrochlorothiazide. This product is suitable for edema diseases, hypertension, central or renal diabetes insipidus, and nephrolithiasis

Rundu Pharma: Hydrochlorothiazide receives approval for chemical raw material drug listing application

According to the Zhitong Finance APP, Rundu Pharma announced that the company recently received the "Approval Notice for the Market Application of Chemical Raw Materials" issued by the National Medical Products Administration for Glucosamine Sulfate Sodium Chloride Compound (hereinafter referred to as "this product"). This product is suitable for the treatment of primary and secondary osteoarthritis. The approval of this product further enriches the company's product categories, enhances the company's market competitiveness, and has a positive impact on the company's future operating performance

Rundu Pharma: The application for the listing of the chemical raw material drug of sodium chloride compound of glucosamine sulfate has been approved

Rundu Pharma(002923.SZ)